drugset / Trial / NCT03785145
MT10109L in the Treatment of Lateral Canthal Lines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL.
Timeline
- Start
- 2018-12-20
- Primary completion
- 2020-02-27
- Completion
- 2021-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NivobotulinumtoxinA | Protein / enzyme biologic | — | — |